Management of DVT in Special Clinical Scenarios

DVT in Pregnancy and Postpartum

The American College of Chest Physicians recommends using low-molecular-weight heparin (LMWH) as first-line therapy throughout pregnancy and continuing anticoagulation for at least 6 weeks postpartum with a minimum total duration of 3 months for pregnant women with acute DVT (Grade 1B) 1
LMWH is strongly preferred over unfractionated heparin (UFH) for both prevention and treatment of VTE in pregnancy, offering superior bioavailability and reduced risk of heparin-induced thrombocytopenia (Grade 1B) 1
Warfarin should be avoided entirely during the first trimester due to teratogenicity and fetal bleeding risks (Grade 1A) 1, 2
Direct oral anticoagulants (DOACs) are absolutely contraindicated in pregnancy (Grade 1C) 3
Anticoagulation should be continued for at least 6 weeks postpartum with a minimum total treatment duration of 3 months from diagnosis (Grade 2C) 1, 4
Postpartum options include prophylactic- or intermediate-dose LMWH, or warfarin with target INR 2.0-3.0 (Grade 2B) 4
LMWH, UFH, and warfarin are all safe during breastfeeding and can be continued (Grade 1A for warfarin/UFH, Grade 1B for LMWH) 1, 3, 6

For patients with DVT and active malignancy, LMWH is the preferred anticoagulant and should be continued indefinitely until there is no evidence of active cancer 7
LMWH is preferred over warfarin for cancer-associated thrombosis (Grade 2B) 7
Extended anticoagulation is recommended regardless of bleeding risk (Grade 2B) 7

In patients with severe renal impairment (CrCl <30 mL/min), dose-adjusted LMWH or UFH with aPTT monitoring should be considered as an alternative 7
LMWH is primarily renally cleared and accumulates in severe renal dysfunction, increasing bleeding risk substantially 7

In patients with hepatic impairment, LMWH or UFH with careful monitoring are preferred, as warfarin dosing becomes unpredictable due to altered vitamin K-dependent clotting factor synthesis 7
Baseline coagulopathy from liver disease does not protect against thrombosis and should not preclude anticoagulation when indicated 7

For patients with recurrent DVT while on therapeutic anticoagulation, verify medication adherence and therapeutic drug levels, then consider increasing anticoagulation intensity or investigating for underlying causes 7
For patients with antiphospholipid antibody syndrome and recurrent thrombosis on warfarin, maintain high-intensity anticoagulation (INR 3.0-4.0) or consider adding low-dose aspirin 75-100 mg daily 1
For pregnant women with recurrent VTE on prophylactic LMWH, escalate to intermediate or therapeutic-dose LMWH immediately 7